Artwork

Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Pediatric atopic dermatitis - What's new? Plus, depression risk with isotretinoin; topical tapinarof is effective

27:29
 
Share
 

Manage episode 277306684 series 2356616
Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dermatology News:

  1. Who’s at risk for depression on isotretinoin?: https://bit.ly/32AioXp
  2. Topical tapinarof effective in pivotal psoriasis trials: https://bit.ly/3pma0o0
  3. Methotrexate users need tuberculosis tests in high-TB areas: https://bit.ly/3f0DcMV

* * *

Keeping up with the literature on atopic dermatitis (AD) is a challenge, with eight new articles posted on PubMed a day in 2020. Vincent A. DeLeo, MD, talks to Lawrence F. Eichenfield, MD, about quality of life in pediatric AD patients and how the condition affects parents/guardians, particularly in the form of sleep disturbances. Dr. Eichenfield also discusses studies that explore the impact of bathing frequency on the severity of AD as well as notable treatment advances in topical and systemic therapies in recent years. Reflecting on future research, Dr. Eichenfield posited if “recognizing significant disease early and instituting our more aggressive therapies early, will that change the development of comorbidities and will that burn out the disease more quickly or get sustained remission or cure as compared to just waiting?”

Article: https://bit.ly/3f0DrHP

Downloadable PDF: https://bit.ly/3lzuUy1

* * *

Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles)

Guest: Lawrence F. Eichenfield, MD (division of pediatric dermatology, departments of dermatology and pediatrics, University of California, San Diego, and Rady Children’s Hospital, San Diego)

Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Eichenfield is an investigator for AbbVie, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. He also is a consultant for Almirall, Dermavant Sciences, Dermira, DS Biopharma, Eli Lilly, Forte Biopharma; Galderma Laboratories, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka Pharmaceutical, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme.

Show notes by: Allegra Sparta, Melissa Sears

* * *

You can find more of our podcasts at http://www.mdedge.com/podcasts

Email the show: podcasts@mdedge.com

  continue reading

106 episodes

Artwork
iconShare
 
Manage episode 277306684 series 2356616
Content provided by MDedge and Medscape Professional Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge and Medscape Professional Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dermatology News:

  1. Who’s at risk for depression on isotretinoin?: https://bit.ly/32AioXp
  2. Topical tapinarof effective in pivotal psoriasis trials: https://bit.ly/3pma0o0
  3. Methotrexate users need tuberculosis tests in high-TB areas: https://bit.ly/3f0DcMV

* * *

Keeping up with the literature on atopic dermatitis (AD) is a challenge, with eight new articles posted on PubMed a day in 2020. Vincent A. DeLeo, MD, talks to Lawrence F. Eichenfield, MD, about quality of life in pediatric AD patients and how the condition affects parents/guardians, particularly in the form of sleep disturbances. Dr. Eichenfield also discusses studies that explore the impact of bathing frequency on the severity of AD as well as notable treatment advances in topical and systemic therapies in recent years. Reflecting on future research, Dr. Eichenfield posited if “recognizing significant disease early and instituting our more aggressive therapies early, will that change the development of comorbidities and will that burn out the disease more quickly or get sustained remission or cure as compared to just waiting?”

Article: https://bit.ly/3f0DrHP

Downloadable PDF: https://bit.ly/3lzuUy1

* * *

Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles)

Guest: Lawrence F. Eichenfield, MD (division of pediatric dermatology, departments of dermatology and pediatrics, University of California, San Diego, and Rady Children’s Hospital, San Diego)

Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Eichenfield is an investigator for AbbVie, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. He also is a consultant for Almirall, Dermavant Sciences, Dermira, DS Biopharma, Eli Lilly, Forte Biopharma; Galderma Laboratories, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka Pharmaceutical, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme.

Show notes by: Allegra Sparta, Melissa Sears

* * *

You can find more of our podcasts at http://www.mdedge.com/podcasts

Email the show: podcasts@mdedge.com

  continue reading

106 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide